Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,676
Change Today 0.00 / 0.00%
Volume 0.0
KMDA On Other Exchanges
Symbol
Exchange
Tel Aviv
NASDAQ GS
As of 10:39 AM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

kamada ltd (KMDA) Snapshot

Open
$1,665
Previous Close
$1,653
Day High
$1,679
Day Low
$1,646
52 Week High
06/9/14 - $3,017
52 Week Low
11/25/14 - $1,160
Market Cap
604.5M
Average Volume 10 Days
136.3K
EPS TTM
$-0.41
Shares Outstanding
36.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KAMADA LTD (KMDA)

kamada ltd (KMDA) Related Businessweek News

No Related Businessweek News Found

kamada ltd (KMDA) Details

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company’s lung disease products include Glassia used in augmentation and maintenance therapy in adults with emphysema due to congenital AAT deficiency (AATD); Bramitob to manage chronic pulmonary infection; and FOSTER for regular treatment of asthma. Its immunoglobulin products comprise KamRAB for prophylaxis against rabies infection; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus; IVIG 5% for the treatment of various immunodeficiency-related conditions; Hepatect CP, a hepatitis B immunoglobulin; Megalotect, a CMV immunoglobulin; and Varitect, a varicella zoster immunoglobulin. The company also provides critical care products, such as Heparin Lock Flush to maintain patency of indwelling IV catheter; Heparin sodium injection to treat thrombo-embolic disorders; Kamacaine 0.5% used as anesthesia or analgesia for surgery, diagnostic, therapeutic, and obstetrical procedures, as well as spinal anesthesia for surgery; and Albumin for maintenance of circulating blood volume. In addition, it offers Transferrin for diagnostic assays and cell cultures; and coagulation factors, including Factor VIII, Factor IX, and Human Transferrin. Further, the company develops various inhaled formulations of AAT to treat AATD, cystic fibrosis, bronchiectasis, type-1 diabetes, chronic obstructive pulmonary diseases, graft-versus-host diseases, and transplantations. It has collaboration partnerships with PARI and Baxter Healthcare Corporation. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. was founded in 1990 and is headquartered in Ness Ziona, Israel.

302 Employees
Last Reported Date: 04/28/15
Founded in 1990

kamada ltd (KMDA) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $455.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $234.0K
Vice President of Operations and Plant Manage...
Total Annual Compensation: $242.0K
Senior Vice President of Business Development
Total Annual Compensation: $207.0K
Vice President of Research and Development
Total Annual Compensation: $212.0K
Compensation as of Fiscal Year 2014.

kamada ltd (KMDA) Key Developments

Kamada Ltd. Proposes Amendments to Articles of Association

Kamada Ltd. announced the AGM to be held on June 30, 2015 to approve certain amendments to Articles of Association.

Kamada Ltd. Reports Updated Data from European Phase 2/3 Clinical Study of Inhaled Alpha-1 Antitrypsin to Treat Aat Deficiency

Kamada Ltd. reported the discussion of the updated data from the company’s European and Canadian Phase 2/3 clinical study of inhaled alpha-1 antitrypsin to treat alpha-1 antitrypsin deficiency during a panel discussion entitled, New Treatment Prospects for AATD Patients: Results from a Phase 2/3 Inhaled AAT Trial, which was chaired by Robert A. Sandhaus, Ph.D., M.D., FCCP, Founder and Director of the Alpha1- Antitrypsin Deficiency Program at National Jewish Health Hospital in Denver, Colorado, and the Clinical Director of the Alpha-1 Foundation. The panel included Key Opinion Leaders who specialize in treating patients with AATD, and was held during the American Thoracic Society 2015 International Conference held from May 15-20, 2015 in Denver, Colorado. In addition to previously announced results that focused on the statistically significant lung function beneficial effect, additional data on the nature of symptoms of the first exacerbation, a clinically important measurement, were reported during the panel session. In the study, three major exacerbation symptoms comprised the severity nature of an exacerbation: dyspnea, sputum volume and sputum color. These symptoms were scored by patients using a daily electronic diary device. The inhaled AAT treated group showed a statistically significant lower symptoms score for patients who experienced first exacerbation versus the placebo group for events: 0-10 days for dyspnea the AAT group scored 11.94 vs 12.25 for placebo, p=0.0243; 0-14 days for dyspnea the AAT group scored 11.58 vs 11.78 for placebo, p=0.0817; 0-10 for sputum volumethe AAT group scored1.27 vs 1.38 for placebo, p=0.0334, 0-14 days for sputum volume the AAT group scored 1.23 vs 1.32 for placebo, p=0.0595. In addition, the inhaled AAT group had a lower percentage of patients who experienced all 3 symptoms during the first exacerbation of the first exacerbation versus the placebo group. Key highlights of the updated data set include: Statistically significant lung function efficacy; Change in the nature of exacerbations; The trial did not achieve statistical significance in primary endpoint of time to first exacerbation; The drug is safe and tolerable.

Kamada Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Revenue Guidance for the Year Ending December 31, 2015

Kamada Ltd. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, total revenues were $8,930,000 against $13,187,000 a year ago. Operating loss was $5,750,000 against $2,707,000 a year ago. Loss before taxes on income was $5,294,000 against $3,099,000 a year ago. Net loss was $5,294,000 or $0.15 per basic and diluted share against $3,122,000 or $0.09 per basic and diluted share a year ago. Net cash used in operating activities was $2,008,000 against $1,545,000 a year ago. Purchase of property and equipment was $509,000 against $616,000 a year ago. Adjusted LBITDA was $4,474,000 against $958,000 a year ago. Adjusted net loss was $4,789,000 against $2,036,000 a year ago. For the year ending December 31, 2015, the company expects total revenue to be between $70 million and $73 million, with revenue from its Distributed Product Segment projected to be between $26 million and $28 million and revenue from its Proprietary Products Segment projected to be between $45 million and $47 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KMDA:IT 1,676.00 0.00

KMDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grifols SA €36.31 EUR -0.84
View Industry Companies
 

Industry Analysis

KMDA

Industry Average

Valuation KMDA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KAMADA LTD, please visit www.kamada.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.